BusinessFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi SyndromeBy Nasdaq OMXDec 26, 2017, 1:30 PM UTC
BusinessStreetwise Reports Examines How One Biotech Receives 'Major Endorsement from World-Leading Pharma Company'By Nasdaq OMXDec 21, 2017, 1:45 PM UTC
BusinessStreetwise Reports Examines How 'Exciting' Collaborations Possible for Biotech's 'Flexible' PlatformBy Nasdaq OMXDec 21, 2017, 1:01 PM UTC
BusinessApellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2By Nasdaq OMXDec 20, 2017, 10:30 PM UTC
BusinessApellis Pharmaceuticals Expands Management Team, Appoints Timothy Sullivan Chief Financial OfficerBy Nasdaq OMXDec 19, 2017, 3:16 PM UTC
BusinessAsklepion Pharmaceuticals Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Program of Intravenous CitrullineBy Nasdaq OMXDec 19, 2017, 2:01 PM UTC
BusinessINSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy in Pediatric PatientsBy Nasdaq OMXDec 19, 2017, 1:01 PM UTC
BusinessCareTrust REIT Announces Quarterly Dividend of $0.185 per ShareBy Nasdaq OMXDec 18, 2017, 1:01 PM UTC
